查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370890

生物製造病毒檢測和定量市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、技術、按應用、最終用戶、地區、競爭細分

Biomanufacturing Viral Detection and Quantifications Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Offering Type, By Technology, By Application, By End-User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球生物製造病毒檢測和定量市場價值為 4.8024 億美元，預計在整個預測期內將呈現強勁成長軌跡，到 2028 年年複合成長率 (CAGR) 為 8.43%，預計價值為2028 年將達到77,173 萬。生物製造病毒檢測和定量涉及利用生物技術方法和技術來開發用於識別和測量病毒的工具、試劑和系統。該領域融合了生物技術、分子生物學和工程學的原理，建立高效可靠的方法來檢測不同樣本（包括臨床、環境和研究環境）中的病毒。該過程包括大規模生產抗體、探針、引子和酶等基本試劑，這些試劑對於透過聚合酶鏈反應(PCR)、酶聯免疫吸附測定(ELISA) 和各種分子生物學等技術進行病毒檢測和定量至關重要化驗。該領域還在生產臨床實驗室和醫療機構用於識別特定病毒感染的診斷試劑盒方面發揮關鍵作用。這些套件包含進行測試和解釋結果所需的所有組件。此外，該領域還有助於開發能夠即時或高通量病毒檢測的先進感測器平台、生物感測器和微流體設備。這些平台通常包括分子識別元件，例如抗體或核酸探針，以捕獲和檢測病毒顆粒。用於病毒檢測和定量的生物製造涵蓋幾個關鍵領域，包括分子診斷、免疫診斷、生物感測器和微流體以及基於細胞的測定。

主要市場促進因素

病毒性疾病發生率的增加推動市場成長：病毒性疾病盛行率的上升是推動全球生物製造病毒檢測和定量市場成長的重要驅動力。世界衛生組織(WHO)估計，目前全球約有一半人口面臨感染登革熱的風險，每年感染人數為100-4億。隨著病毒性疾病變得更加普遍，早期檢測和診斷對於及時的醫療介入變得至關重要。生物製造的病毒檢測工具（例如診斷試劑盒和檢測方法）為醫療保健專業人員提供了準確、快速的方法來檢測患者樣本中的病毒。這有助於快速治療和遏制，有助於減少感染的傳播並改善患者的治療效果。病毒性疾病的增加凸顯了強力的監測和流行病學監測的重要性。生物製造的病毒檢測產品透過追蹤病毒爆發、了解疾病模式和評估控制措施的有效性，為這些努力做出了貢獻。這些資訊對於公共衛生機構、政府和醫療保健提供者做出明智的決策至關重要。

市場概況
預測期 2024-2028
2022 年市場規模 4.8024億美元
2028 年市場規模 77173萬美元
2023-2028 年年複合成長率 8.43%
成長最快的細分市場 耗材
最大的市場 亞太地區

診斷技術的進步推動市場成長：診斷技術的進步在推動全球生物製造病毒檢測和定量市場方面發揮關鍵作用。這些創新提高了病毒檢測方法的準確性、速度、靈敏度和可擴展性，從而帶來更廣泛的應用，並增加了對生物製造的病毒檢測和定量產品的需求。新的診斷技術利用創新的分子和免疫學技術，在檢測病毒病原體方面實現更高的靈敏度和特異性。生物製造支持生產高度特異性的試劑，例如抗體和探針，這對於精確的病毒檢測至關重要。微流體、小型化和感測器技術的進步促進了攜帶式快速照護端 (POC) 診斷設備的開發。這些設備有助於現場病毒檢測，減少樣本運輸的需要並實現即時決策。生物製造有助於生產用於 POC 測試的組件。現代診斷技術能夠在一次檢測中同時檢測多個病毒標靶。這種多重功能提高了效率、減少了測試時間並節省了樣品體積。生物製造支持多重檢測和試劑組的創建。數位 PCR 和液滴數位 PCR (ddPCR) 等定量技術可準確測量病毒量。生物製造的標準品和對照品對於建立校準曲線和確保準確定量至關重要。自動化、機器人技術和高通量平台增強了高效處理大量樣品的能力。生物製造的試劑和檢測組件有助於擴大病毒檢測工作流程以達到篩選目的。基於奈米技術的診斷平台提供高靈敏度和快速檢測能力。生物製造有助於生產用於病毒檢測的奈米感測器和奈米顆粒。下一代定序 (NGS) 技術可以對病毒基因組進行全面分析，從而深入了解病毒多樣性、演化和傳播。生物製造支持NGS文庫的製備和定序試劑的生產。

大流行病的準備和反應推動了市場成長：大流行病的準備和回應極大地推動了全球生物製造病毒檢測和定量市場。從以往的大流行和當前疫情中汲取的經驗教訓強調了強大的病毒檢測能力的重要性。 H1N1 流感和 COVID-19 大流行等備受矚目的流行病強調需要有效的病毒檢測工具來識別和控制疫情。這種認知導致對生物製造基礎設施的投資增加，以開發和生產診斷試劑、試劑盒和檢測方法。在大流行期間，迫切需要快速、準確的診斷測試來識別感染者。生物製造有助於快速開發、驗證和生產診斷工具，以便及時篩檢和監測，從而實現早期病例識別和遏制。建立緊急應變系統和基礎設施對於應對大流行病至關重要。生物製造透過提供病毒抗原、抗體和分子探針等診斷測試組件發揮關鍵作用。國家、研究機構、診斷製造商和醫療保健提供者之間的合作對於應對大流行至關重要。生物製造商透過提供病毒檢測組件和專業知識、促進創新和知識共享做出貢獻。大流行加速了研究和開發，以增強診斷技術。生物製造支持新型診斷方法的試劑和材料的生產，提高病毒檢測的敏感度、特異性和速度。

主要市場挑戰

快速進化的病毒：病毒的快速演化為全球生物製造病毒檢測和定量市場帶來了重大挑戰。病毒突變可以改變檢測分析所針對的基因序列。如果突變發生在對檢測檢測至關重要的區域，則可能會導致假陰性，即儘管存在病毒，但檢測仍無法檢測到病毒。為了解決新出現的病毒變異，需要不斷調整檢測方法。突變會影響檢測試劑（例如抗體和引子）的結合親和力，從而可能降低測定的靈敏度或特異性。生物製造商必須不斷調整試劑，以保持針對不斷進化的病毒株的最佳性能。

複雜樣品基質：複雜樣品基質對全球生物製造病毒檢測和定量市場提出了重大挑戰。複雜樣本基質是指在臨床、環境或其他測試病毒存在的樣本中發現的多種物質混合物。這些物質會干擾病毒檢測方法並影響結果準確性。複雜樣本（例如血液、唾液或環境樣本）中的成分可能與檢測試劑、抗體或引子相互作用，導致假陽性或陰性。蛋白質、脂質和抑制劑等物質會阻礙檢測分子與病毒標靶的結合。複雜的基質可以稀釋病毒標靶或降低其濃度，使檢測變得更加困難。這會降低檢測靈敏度並導致漏檢或定量不準確。

高研發成本：高研發（R＆D）成本是全球生物製造病毒檢測和定量市場的重大挑戰。開發、最佳化和驗證

主要市場趨勢

新興傳染病的準備：新興傳染病（EID）的準備是全球生物製造病毒檢測和定量市場的重要趨勢。這一趨勢反映出人們越來越認知到需要做好充分準備來快速應對新的和意外的傳染病爆發。 EID 準備工作推動了快速、準確的病毒檢測測試的發展，這些測試可以在疫情爆發期間快速部署。生物製造商專注於創建能夠以高靈敏度和特異性檢測新病原體或變異體的診斷檢測方法。應對 EID 需要適應性強的製造能力，以快速生產針對新出現病原體的試劑、試劑盒和檢測方法。這可能涉及靈活的生產流程和可擴展的製造設施。在 EID 爆發期間，對新病毒檢測方法進行嚴格和快速的驗證變得至關重要。生物製造商需要驗證並確保針對新病毒株的檢測性能，以保持可靠性。生物製造公司、研究機構、公共衛生機構和政府之間的合作加速了有效病毒檢測解決方案的開發和推廣。在 EID 爆發期間，監管機構可能會加快新病毒檢測產品的核准流程，以促進快速部署。生物製造商需要與監管機構密切合作。生物製造的病毒檢測產品在監測新出現的病原體傳播和影響的全球監測工作中發揮關鍵作用。早期發現和監測對於有效應對疫情至關重要。這些工具對於評估 EID 爆發期間的疫苗功效至關重要，有助於追蹤病原體流行情況和監測疫苗接種活動的影響。

細分市場洞察

產品類型洞察： 2022 年，消耗品細分市場在生物製造病毒檢測和定量市場中佔據主導地位，預計在未來幾年將繼續擴張。耗材是病毒檢測工作流程的重要組成部分，需要根據使用情況定期補充。這會導致重複購買，為生物製造公司提供穩定的收入來源。病毒檢測和定量分析在臨床實驗室、研究機構和公共衛生機構中常規進行，導致對檢測的持續需求。不同的病毒標靶、樣本類型和檢測格式需要定製或專門的耗材，為生物製造商提供一系列產品來滿足特定的測試要求。高品質的耗材對於準確可靠的病毒檢測至關重要，需要嚴格的品質控制和驗證以確保一致的性能。預計 2023 年至 2030 年該細分市場將經歷最高的年複合成長率 (CAGR)。

技術洞察： 2022年，PCR（聚合酶鍊式反應）技術領域主導了生物製造病毒檢測和定量市場，預計在可預見的未來將繼續成長。 PCR 以其高靈敏度和特異性而聞名，使其成為準確檢測低病毒量的理想選擇，尤其是在疫情爆發的早期階段。 PCR 適用於病毒遺傳物質的定性（存在/不存在）和定量（病毒量）分析。定量資料有助於疾病監測、評估治療效果和研究應用。 PCR 可以針對特定的病毒基因或區域，因此可以針對各種病毒目標進行客製化。這種多功能性使其適合檢測多種病毒病原體。即時 PCR (qPCR) 等變異體通常可在數小時內提供快速結果，這對於快速臨床決策和疫情應對至關重要。多重 PCR 能夠在一次反應中同時檢測多個病毒標靶，從而提高效率並節省樣本量，這對於高效篩檢和監測至關重要。跨實驗室的標準化 PCR 檢測可確保結果的一致性和可比性，這對於準確的疾病監測和研究合作至關重要。 PCR 技術已經成熟並在臨床環境中被廣泛接受，許多檢測方法已獲得監管部門批准用於診斷。

應用洞察：到 2022 年，血液和血液製品製造領域在生物製造病毒檢測和定量市場中佔據主導地位，預計將繼續其成長軌跡。血液和血液製品是醫療保健系統不可或缺的一部分，確保其安全免受病毒污染至關重要。病毒檢測用於篩檢捐血者是否存在感染性病毒，例如 HIV、乙型和丙型肝炎以及人類 T 細胞淋巴細胞病毒 (HTLV)。這對於防止病毒透過輸血傳播至關重要。血漿用於生產各種血漿衍生產品，包括凝血因子和免疫球蛋白，這強調了病毒檢測在確保無污染血漿捐贈方面的重要性。

最終用戶見解： 2022 年，臨床實驗室和醫院在生物製造病毒檢測和定量市場中佔據主導地位，預計將繼續擴張。臨床實驗室和醫院是用於診斷目的的病毒檢測和定量技術的主要使用者。他們進行常規病毒感染檢測，以支持患者護理和治療決策。生物製藥公司在各個藥物開發階段採用病毒檢測方法，包括研究、品質控制以及疫苗和單株抗體等生物製品的生產。學術和研究機構利用病毒檢測和定量技術進行基礎研究、流行病學研究和新診斷方法的開發。

區域見解：亞太地區成為全球生物製造病毒檢測和定量市場的領導者。亞太地區擁有世界上最大且成長最快的人口，對醫療保健服務的需求不斷成長，包括生物製造病毒檢測和定量。該地區愛滋病毒、B型肝炎和丙型肝炎等病毒性疾病的盛行率也很高，因此需要病毒檢測和定量測試來診斷和管理這些疾病。

結論：全球生物製造病毒檢測和定量市場呈現出巨大的成長潛力，其促進因素包括病毒性疾病發病率的增加、診斷技術的進步以及大流行防範和應對的必要性。需要應對快速進化的病毒、複雜的樣本基質以及高昂的研發成本等挑戰。主要市場趨勢包括強調新興傳染病的防範。產品類型、技術、應用和最終用戶等細分市場呈現不同的動態，其中耗材、PCR 技術、血液和血液製品製造以及臨床實驗室和醫院發揮關鍵作用。此外，在人口規模和醫療保健需求的推動下，亞太地區成為市場的領導者。這些見解強調了全球生物製造病毒檢測和量化領域的重大機會和挑戰。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球生物製造病毒檢測與定量市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（消耗品、儀器、服務）
    • 依技術（PCR、ELISA、流式細胞儀、噬菌斑測定等）
    • 按應用（血液和血液製品製造、疫苗和療法製造、細胞和基因治療產品製造、幹細胞產品製造、組織和組織產品製造）
    • 按最終用戶（生命科學公司、測試實驗室、CRO 和 CDMO）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美生物製造病毒檢測與定量市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲生物製造病毒檢測與定量市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區生物製造病毒檢測與定量市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲生物製造病毒檢測與定量市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲生物製造病毒檢測和定量市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非生物製造病毒檢測和定量
    • 沙烏地阿拉伯生物製造病毒檢測和定量
    • 阿拉伯聯合大公國生物製造病毒檢測與定量

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Danaher Corporation
    • Merck KGaA
    • New England Biolabs
    • TAKARA HOLDINGS INC.
    • Thermo Fisher Scientific Inc.
    • Agilent Technologies, Inc.
    • Sartorius AG
    • Charles River Laboratories
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.

第 16 章：策略建議

簡介目錄
Product Code: 15881

The Global Biomanufacturing Viral Detection and Quantifications Market recorded a value of USD 480.24 Million in 2022, with a projected strong growth trajectory throughout the forecast period, showcasing a Compound Annual Growth Rate (CAGR) of 8.43% until 2028 and expected to be valued at USD 771.73 Million in 2028. Biomanufacturing Viral Detection and Quantifications involve the utilization of biotechnological methods and techniques to develop tools, reagents, and systems used in identifying and measuring viruses. This field amalgamates principles from biotechnology, molecular biology, and engineering to establish efficient and reliable methods for detecting viruses in diverse samples, including clinical, environmental, and research settings. The process encompasses large-scale production of essential reagents such as antibodies, probes, primers, and enzymes, vital for virus detection and quantification through techniques like Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), and various molecular biology assays. The domain also plays a pivotal role in producing diagnostic kits used in clinical laboratories and healthcare facilities for identifying specific viral infections. These kits encompass all the necessary components to conduct tests and interpret results. Furthermore, the arena contributes to the development of advanced sensor platforms, biosensors, and microfluidic devices capable of real-time or high-throughput virus detection. These platforms often include molecular recognition elements such as antibodies or nucleic acid probes to capture and detect viral particles. Biomanufacturing for viral detection and quantification encompasses several key areas including Molecular Diagnostics, Immunodiagnostics, Biosensors and Microfluidics, and Cell-Based Assays.

Key Market Drivers

Increasing Incidence of Viral Diseases Drive the Market Growth: The rising prevalence of viral diseases is a significant driver propelling the growth of the global biomanufacturing viral detection and quantification market. The World Health Organization (WHO) estimates that approximately half of the global population is currently at risk of contracting dengue, with an annual infection rate of 100-400 million. As viral diseases become more widespread, early detection and diagnosis become crucial for timely medical interventions. Bio manufactured viral detection tools, such as diagnostic kits and assays, provide healthcare professionals with accurate and rapid means to detect viruses in patient samples. This facilitates swift treatment and containment, which aids in reducing the spread of infections and enhancing patient outcomes. The increase in viral diseases underscores the importance of robust surveillance and epidemiological monitoring. Bio manufactured viral detection products contribute to these efforts by enabling the tracking of viral outbreaks, understanding disease patterns, and evaluating control measures' effectiveness. This information is vital for informed decision-making by public health agencies, governments, and healthcare providers.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 480.24 Million
Market Size 2028USD 771.73 Million
CAGR 2023-20288.43%
Fastest Growing SegmentConsumables
Largest MarketAsia Pacific

Advancement In Diagnostic Technology Propels the Market Growth: Technological advancements in diagnostics play a pivotal role in driving the global biomanufacturing viral detection and quantification market. These innovations enhance the accuracy, speed, sensitivity, and scalability of viral detection methods, leading to broader applications and increased demand for bio manufactured viral detection and quantification products. New diagnostic technologies leverage innovative molecular and immunological techniques to achieve higher sensitivity and specificity in detecting viral pathogens. Biomanufacturing supports the production of highly specific reagents, such as antibodies and probes, essential for precise viral detection. Microfluidics, miniaturization, and sensor technologies advancements enable the development of portable and rapid Point-of-Care (POC) diagnostic devices. These devices facilitate on-site virus detection, reducing the need for sample transportation and enabling real-time decision-making. Biomanufacturing contributes to the production of components for POC tests. Modern diagnostic technologies enable the simultaneous detection of multiple viral targets in a single assay. This multiplexing capability improves efficiency, reduces testing time, and conserves sample volume. Biomanufacturing supports the creation of multiplex assays and reagent panels. Quantitative techniques like Digital PCR and droplet digital PCR (ddPCR) provide accurate measurements of viral load. Bio manufactured standards and controls are pivotal for establishing calibration curves and ensuring accurate quantification. Automation, robotics, and high-throughput platforms enhance the ability to process a large number of samples efficiently. Bio manufactured reagents and assay components facilitate scaling up viral detection workflows for screening purposes. Nanotechnology-based diagnostic platforms offer high sensitivity and rapid detection capabilities. Biomanufacturing contributes to the production of nano sensors and nanoparticles used in viral detection. Next-Generation Sequencing (NGS) technologies enable comprehensive analysis of viral genomes, providing insights into viral diversity, evolution, and transmission. Biomanufacturing supports the preparation of NGS libraries and the production of sequencing reagents.

The Pandemic Preparedness and Response Drives the Market Growth: Pandemic preparedness and response significantly drive the global biomanufacturing viral detection and quantification market. Lessons learned from previous pandemics and ongoing outbreaks emphasize the importance of robust viral detection capabilities. High-profile pandemics such as H1N1 influenza and the COVID-19 pandemic underscore the need for effective viral detection tools to identify and control outbreaks. This awareness results in increased investment in biomanufacturing infrastructure to develop and produce diagnostic reagents, kits, and assays. During pandemics, rapid and accurate diagnostic tests are urgently required to identify infected individuals. Biomanufacturing facilitates the swift development, validation, and production of diagnostic tools for timely screening and surveillance, enabling early case identification and containment. The establishment of emergency response systems and infrastructure is crucial for pandemic preparedness. Biomanufacturing plays a pivotal role by supplying components for diagnostic tests such as viral antigens, antibodies, and molecular probes. Collaborative efforts between countries, research institutions, diagnostic manufacturers, and healthcare providers are essential to pandemic response. Biomanufacturers contribute by providing viral detection components and expertise, fostering innovation and knowledge sharing. Pandemics accelerate research and development to enhance diagnostic technologies. Biomanufacturing supports the production of reagents and materials for novel diagnostic methods, enhancing the sensitivity, specificity, and speed of viral detection.

Key Market Challenges

Rapidly Evolving Viruses: The swift evolution of viruses presents significant challenges to the global biomanufacturing viral detection and quantification market. Viral mutations can alter the genetic sequences targeted by detection assays. If a mutation occurs in a region crucial for assay detection, it can result in false negatives, where the assay fails to detect the virus despite its presence. Continuous adaptation of assays is necessary to account for emerging viral variants. Mutations can affect the binding affinity of detection reagents, such as antibodies and primers, potentially reducing assay sensitivity or specificity. Biomanufacturers must continuously adjust reagents to maintain optimal performance against evolving viral strains.

Complex Sample Matrices: Complex sample matrices pose a significant challenge in the global biomanufacturing viral detection and quantification market. Complex sample matrices refer to the diverse mixture of substances found in clinical, environmental, or other samples tested for viral presence. These substances can interfere with viral detection methods and impact result accuracy. Components in complex samples, such as blood, saliva, or environmental samples, can interact with detection reagents, antibodies, or primers, leading to false positives or negatives. Substances like proteins, lipids, and inhibitors can hinder the binding of detection molecules to viral targets. Complex matrices can dilute viral targets or lower their concentration, making detection more difficult. This can reduce assay sensitivity and result in missed infections or inaccurate quantification.

High Research and Development Costs: High research and development (R&D) costs represent a significant challenge in the global biomanufacturing viral detection and quantification market. Developing, optimizing, and validating

new viral detection methods and products can incur substantial expenses. The costs can strain the financial resources of biomanufacturers, particularly smaller companies and startups. Limited funds may hinder their ability to invest in innovative research and product development. High R&D costs can act as entry barriers for new market players, limiting competition and potentially slowing innovation. This can lead to a lack of diverse and cutting-edge viral detection solutions. Lengthy and expensive R&D processes can delay the introduction of new products to the market. Delays could impact the availability of timely and up-to-date viral detection tools during outbreaks or emerging viral threats. Rigorous validation and testing of new viral detection methods are essential for accuracy and reliability, contributing to higher R&D costs. This is particularly critical in the context of complex sample matrices and rapidly evolving viruses. Developing high-quality reagents and materials suitable for viral detection methods requires investments in research, manufacturing, and quality control.

Key Market Trends

Emerging Infectious Diseases Preparedness: Preparedness for emerging infectious diseases (EIDs) is a significant trend in the global biomanufacturing viral detection and quantification market. This trend reflects the growing recognition of the need to be well-equipped to rapidly respond to new and unexpected infectious disease outbreaks. EID preparedness drives the development of rapid and accurate viral detection tests that can be quickly deployed during outbreaks. Biomanufacturers focus on creating diagnostic assays that can detect new pathogens or variants with high sensitivity and specificity. Responding to EIDs requires adaptable manufacturing capabilities to swiftly produce reagents, kits, and assays for emerging pathogens. This may involve flexible production processes and scalable manufacturing facilities. Rigorous and expedited validation of new viral detection assays becomes crucial during EID outbreaks. Biomanufacturers need to validate and ensure assay performance against new viral strains to maintain reliability. Collaboration between biomanufacturing companies, research institutions, public health agencies, and governments accelerates the development and distribution of effective viral detection solutions. Regulatory authorities may expedite the approval process for new viral detection products during EID outbreaks to facilitate rapid deployment. Biomanufacturers need to closely collaborate with regulatory bodies. Biomanufactured viral detection products play a critical role in global surveillance efforts to monitor emerging pathogen spread and impact. Early detection and monitoring are essential for effective outbreak response. These tools are vital for assessing vaccine efficacy during EID outbreaks, aiding in tracking pathogen prevalence and monitoring vaccination campaign impact.

Segmental Insights

Offering Type Insights: In 2022, the Consumables Segment dominated the Biomanufacturing Viral Detection and Quantifications market and is expected to continue its expansion in the years ahead. Consumables are essential components of viral detection workflows, requiring regular replenishment due to usage. This results in repeat purchases, providing a steady revenue stream for biomanufacturing companies. Viral detection and quantification assays are performed routinely in clinical laboratories, research institutions, and public health agencies, leading to consistent demand for testing. Different viral targets, sample types, and assay formats necessitate customized or specialized consumables, offering biomanufacturers an array of products to meet specific testing requirements. High-quality consumables are crucial for accurate and reliable viral detection, subjected to rigorous quality control and validation to ensure consistent performance. The segment is projected to experience the highest Compound Annual Growth Rate (CAGR) from 2023 to 2030.

Technology Insights: In 2022, the PCR (Polymerase Chain Reaction) Technology Segment dominated the Biomanufacturing Viral Detection and Quantifications market and is anticipated to continue its growth in the foreseeable future. PCR is renowned for its high sensitivity and specificity, making it ideal for accurately detecting even low viral loads, especially in the early stages of an outbreak. PCR is applicable for both qualitative (presence/absence) and quantitative (viral load) analysis of viral genetic material. The quantitative data aids in disease monitoring, assessing treatment efficacy, and research applications. PCR can target specific viral genes or regions, allowing customization for various viral targets. This versatility makes it suitable for detecting a wide array of viral pathogens. Variants such as Real-Time PCR (qPCR) provide rapid results, often within hours, essential for swift clinical decision-making and outbreak response. Multiplex PCR enables simultaneous detection of multiple viral targets in a single reaction, enhancing efficiency and conserving sample volume, crucial for efficient screening and surveillance. Standardized PCR assays across laboratories ensure consistent and comparable results, critical for accurate disease monitoring and research collaboration. PCR technology is well-established and widely accepted in clinical settings, with numerous assays receiving regulatory approvals for diagnostic use.

Application Insights: In 2022, the Blood and Blood Products Manufacturing Segment dominated the Biomanufacturing Viral Detection and Quantifications market and is projected to continue its growth trajectory. Blood and blood products are integral components of healthcare systems, and ensuring their safety from viral contamination is of paramount importance. Viral detection assays are used to screen blood donations for infectious viruses like HIV, hepatitis B and C, and human T-cell lymphotropic virus (HTLV). This is crucial in preventing virus transmission through blood transfusions. Blood plasma is utilized for producing various plasma-derived products, including clotting factors and immunoglobulins, underscoring the importance of viral detection in ensuring contamination-free plasma donations.

End-User Insights: In 2022, Clinical Laboratories and Hospitals dominated the Biomanufacturing Viral Detection and Quantifications market and are predicted to continue their expansion. Clinical laboratories and hospitals are primary users of viral detection and quantification technologies for diagnostic purposes. They conduct routine viral infection testing to support patient care and treatment decisions. Biopharmaceutical companies employ viral detection methods across various drug development stages, including research, quality control, and production of biologics like vaccines and monoclonal antibodies. Academic and research institutions leverage viral detection and quantification technologies for basic research, epidemiological studies, and new diagnostic method development.

Regional Insights: The Asia-Pacific region emerges as a leader in the Global Biomanufacturing Viral Detection and Quantifications Market. With the world's largest and fastest-growing population, the Asia-Pacific region witnesses increasing demand for healthcare services, including biomanufacturing viral detection and quantification. The region also experiences a high prevalence of viral diseases such as HIV, hepatitis B, and hepatitis C, driving the need for viral detection and quantification tests to diagnose and manage these diseases.

In Conclusion: The Global Biomanufacturing Viral Detection and Quantifications Market presents significant growth potential driven by the increasing incidence of viral diseases, advancements in diagnostic technology, and the imperative for pandemic preparedness and response. Challenges such as rapidly evolving viruses, complex sample matrices, and high research and development costs need to be navigated. Key market trends include the emphasis on emerging infectious diseases preparedness. Segments like offering types, technology, applications, and end-users showcase varied dynamics, with consumables, PCR technology, blood and blood product manufacturing, and clinical laboratories and hospitals playing pivotal roles. Moreover, the Asia-Pacific region emerges as a frontrunner in the market, driven by its population size and healthcare demands. These insights underscore the significant opportunities and challenges within the global biomanufacturing viral detection and quantification landscape.

Key Market Players

  • Danaher Corporation
  • Merck KGaA
  • New England Biolabs
  • TAKARA HOLDINGS INC.
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Sartorius AG
  • Charles River Laboratories
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc

Report Scope:

In this report, the Global Biomanufacturing Viral Detection and Quantifications Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biomanufacturing Viral Detection and Quantifications Market, By Offering Type:

  • Consumables
  • Instruments
  • Services

Biomanufacturing Viral Detection and Quantifications Market, By Technology:

  • PCR
  • ELISA
  • Flow Cytometry
  • Plaque Assay
  • Others

Biomanufacturing Viral Detection and Quantifications Market, By Application:

  • Blood and Blood Products Manufacturing
  • Vaccines and Therapeutics Manufacturing
  • Cellular and Gene Therapy Products Manufacturing
  • Stem Cell Products Manufacturing
  • Tissue and Tissue Products Manufacturing

Biomanufacturing Viral Detection and Quantifications Market, By End User:

  • Life Science Companies
  • Testing Laboratories
  • CROs and CDMOs

Global Biomanufacturing Viral Detection and Quantifications Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Biomanufacturing Viral Detection and Quantifications Market.

Available Customizations:

  • Global Biomanufacturing Viral Detection and Quantifications Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Offering Type (Consumables, instruments, Services)
    • 5.2.2. By Technology (PCR, ELISA, FLOW Cytometry, Plaque Assay, Others)
    • 5.2.3. By Application (Blood and Blood Products Manufacturing, Vaccine and Therapeutics Manufacturing, Cellular and Gene Therapy Products Manufacturing, Stem Cell Products Manufacturing, Tissue and tissue Products Manufacturing)
    • 5.2.4. By End-User (Life Science Companies, testing Laboratories, CROs and CDMOs)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Offering Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Offering Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-User
    • 6.3.2. Mexico Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Offering Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-User
    • 6.3.3. Canada Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Offering Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-User

7. Europe Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Offering Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Offering Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-User
    • 7.3.2. Germany Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Offering Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-User
    • 7.3.3. United Kingdom Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Offering Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-User
    • 7.3.4. Italy Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Offering Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Offering Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-User

8. Asia-Pacific Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Offering Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Offering Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Offering Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-User
    • 8.3.3. South Korea Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Offering Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-User
    • 8.3.4. Japan Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Offering Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Offering Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-User

9. South America Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Offering Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Offering Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-User
    • 9.3.2. Argentina Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Offering Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-User
    • 9.3.3. Colombia Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Offering Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-User

10. Middle East and Africa Biomanufacturing Viral Detection and Quantifications Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Offering Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Offering Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-User
    • 10.3.2. Saudi Arabia Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Offering Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-User
    • 10.3.3. UAE Biomanufacturing Viral Detection and Quantifications Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Offering Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Danaher Corporation
    • 15.6.2. Merck KGaA
    • 15.6.3. New England Biolabs
    • 15.6.4. TAKARA HOLDINGS INC.
    • 15.6.5. Thermo Fisher Scientific Inc.
    • 15.6.6. Agilent Technologies, Inc.
    • 15.6.7. Sartorius AG
    • 15.6.8. Charles River Laboratories
    • 15.6.9. Bio-Rad Laboratories, Inc.
    • 15.6.10. PerkinElmer, Inc.

16. Strategic Recommendations